Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multivitamins may protect against nutrient loss in GLP-1 users

NCT ID NCT07234916

Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking a daily multivitamin can prevent vitamin and mineral deficiencies in people using GLP-1 drugs (like tirzepatide) for weight loss. About 246 adults with obesity who have been on a stable GLP-1 dose for at least 3 months will be randomly assigned to receive either a multivitamin or a placebo for 12 months. Researchers will measure key nutrients like vitamin B12, vitamin D, and iron in the blood to see if supplementation makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multivitamin supplement
What this could lead to
If it works, this could show that taking a daily multivitamin helps prevent nutrient deficiencies in people using GLP-1 weight-loss drugs.
What could go wrong
This is a small, early-stage trial focused on blood levels, not on preventing actual health problems. The results may not apply to everyone, and multivitamins might not make a meaningful difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 246 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 to 70 years. * Start with the use of Tirzepatide GLP-1 receptor agonists and for at least 3 months with stable dosing before randomization. * BMI ≥30 kg/m² or ≥27 kg/m² with obesity-associated medical problems (such as type 2 diabetes, hypertension, or dyslipidemia) at the start of GLP-1 therapy * Willing and able to provide informed consent * Able to comply with study procedures and follow-up visits * Own vitamins should be completely discontinued 2 weeks before the start Exclusion Criteria: * Known allergy or hypersensitivity to any components of the multivitamin supplement * Current use of other vitamin or mineral supplements * Pregnancy or planning pregnancy during the study period * Patients who follow a vegan diet. * Active malignancy or ongoing cancer treatment * Severe kidney disease (eGFR \<30 mL/min/1.73m²) * Severe liver disease (Child-Pugh C) * History of metabolic bariatric surgery * Participation in other clinical trials within the past 3 months * Any condition that, in the investigator's opinion, would interfere with study participation or compromise patient safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLP - 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Malnutrition nutritional deficiency disease Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLP - 1 Nutritional deficiencies Obese patients Weight loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erasmus MC

    Rotterdam, Netherlands

  • WeightWorks Clinics

    Amersfoort, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.